Allergic reactions, such as urticaria, itching and anaphylactic shock, often complicate the course of cystic echinococcosis (CE). To investigate the role of the IgE-immunoreactive recombinant Echinococcus granulosus elongation factor-1 beta/delta (EgEF-1 beta/delta) in the allergic disorders during CE we determined humoral and cell-mediated responses to this antigen in patients with CE grouped according to the clinical presence or absence of allergic reactions. Immunoblotting analysis showed that serum IgE-binding reactivity to EgEF-1 beta/delta differed significantly in patients with and without allergic reactions (38 of 42, 90% vs. 31 of 56, 56%; P < 10(-4)). EgEF-1 beta/delta induced a proliferative response in 14 of 19 (74%) patients' peripheral blood mononuclear cells (PBMC) irrespective of the allergic manifestations and skewed Th1/Th2 cytokine activation towards a preferentially Th2 polarization. Epitope mapping identified an immunodominant epitope of 18 residues with 78% identity and 89% similarity with an IgE-immunoreactive Strongyloides stercoralis antigen. Overall these findings suggest that EgEF-1 beta/delta is an allergenic molecule that may be a general marker of the intensity of CE immune response and that could lead to a deeper understanding of the specific antigen-induced mechanisms underlying allergic reactions in the human host.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1906106PMC
http://dx.doi.org/10.1046/j.1365-2249.2001.01569.xDOI Listing

Publication Analysis

Top Keywords

allergic reactions
16
egef-1 beta/delta
16
echinococcus granulosus
8
allergic manifestations
8
cystic echinococcosis
8
allergic
7
beta/delta
6
elongation factor
4
factor beta/delta
4
beta/delta echinococcus
4

Similar Publications

Background: The buildup of methylparaben (MP), a broad-spectrum antimicrobial preservative with endocrine-disrupting properties, in environmental sources, especially aquatic systems, has become a significant concern due to its adverse health effects, including allergic reactions, promoting the risk of developing cancer, and inducing reproductive disorders. Hence, introducing inexpensive and easy-to-use monitoring devices for rapid, selective, and sensitive detection and quantification of MP is highly desirable. In this context, electrochemical platforms have proven to be attractive options due to their remarkable features, such as ease of fabrication and use, short response time, and acceptable sensitivity, accuracy, and selectivity.

View Article and Find Full Text PDF

Background: Bee venom consists of more than 50 % melittin (MLT), which has anti-cancer, anti-inflammatory, and antimicrobial properties. Bee venom also contains toxic components such as phospholipase A2 (PLA2) and hyaluronidase (HYA), which cause allergic reactions, so the toxic components must be removed to use MLT. In previous studies, analytical methods were used to separate MLT.

View Article and Find Full Text PDF

Acute generalized exanthematous pustulosis is a severe cutaneous adverse reaction characterized by the rapid onset of nonfollicular, sterile pustules on an erythematous base, typically accompanied by fever (≥38 °C), neutrophilia (7.0 × 10⁹/L), and characteristic histopathological features. This case report presents the first documented instance of acute generalized exanthematous pustulosis after hyaluronic acid viscosupplementation.

View Article and Find Full Text PDF

Hazelnut oral immunotherapy desensitizes hazelnut but not other tree nut allergies (Nut CRACKER Study).

J Allergy Clin Immunol Pract

January 2025

Institute of Allergy, Immunology and Pediatric Pulmonology, Yitzhak Shamir Medical Center; Department of Pediatrics, Faculty of Medicine, Tel Aviv University.

Background: Data on oral immunotherapy (OIT) for hazelnut allergy is limited and its potential to cross-desensitize for other nuts is unknown.

Objective: To study the efficacy and safety of hazelnut OIT in desensitizing hazelnut and additional tree nuts.

Methods: A prospective observational study of 30 hazelnut allergic patients aged ≥4 years who underwent hazelnut OIT.

View Article and Find Full Text PDF

Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes. Patients received Tapinarof or vehicle cream QD for 8 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!